Silvia Presas‐Rodríguez

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration

Barbara Willekens, Silvia Presas‐Rodríguez, MJ Mansilla et al. · BMJ Open · 2019 · 101 citations · Full text

Life Sciences, Immunology, Neurology +17

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

María Sepúlveda, Marta Aldea, Domingo Escudero et al. · Multiple Sclerosis Journal · 2017 · 100 citations · Full text

Medicine, Neurology, Disease Surveillance +14

Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

Bibiana Quirant‐Sánchez, José Vicente Hervás, Aina Teniente‐Serra et al. · CNS Neuroscience & Therapeutics · 2018 · 42 citations · Full text

Life Sciences, Immunology, Neurology +17

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis

Bibiana Quirant‐Sánchez, María José Mansilla, Juan Navarro‐Barriuso et al. · Biomedicines · 2021 · 29 citations · Full text

Life Sciences, Immunology, Pathobiology +17

Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients

Joan Puñet‐Ortiz, José Vicente Hervás, Aina Teniente‐Serra et al. · Cytometry Part B Clinical Cytometry · 2017 · 22 citations · Full text

Life Sciences, Immunology, Pharmacology +15